Given truncating CHEK2 PGVs have been associated with a relative risk of breast cancer of 2.2,9 a high risk of contralateral disease,32 and are enriched in this cohort and others, this would substantiate inclusion of testing for CHEK2 PGVs in clinical diagnostic breast cancer genetic testing panels. This evidence concerns the gene CHEK2 and breast carcinoma.